Sanofi

(Image: Getty/Ktsimage)

Regeneron in $1bn RNAi pact with Alnylam

By Ben Hargreaves

Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers